Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-82|1|362|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-83|1|487|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor\Kid interst.fibrosis, glomerul.hyaliniz. & casts,MPATH: 218 - neoplasm|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-84|1|500|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-85|1|503|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-86|1|630|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-87|1|632|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-88|1|666|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fibrous nodule|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-89|1|773|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-90|1|805|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv PMNs & MNs inflt|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-649|1|672|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv necrosis|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-650|1|683|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Kid interstitial lym.inflt|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-651|1|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-652|1|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-654|1|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-655|1|853|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Liv fatty degeneration|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-656|1|882|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-657|1|895|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid glomerular mineralization|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-658|1|896|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-659|1|424|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-660|1|945|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-661|1|650|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-662|1|745|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|Liver fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-664|1|757|Neoplasia malignant|Other local manifestations and miscellaneus|Abdominal sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-665|1|837|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-666|1|873|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-667|1|913|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-668|1|932|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-669|1|942|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-809|1|387|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-810|1|896|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-812|1|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-813|1|699|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-814|1|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-815|1|848|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-816|1|861|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.fibroadenocarcinoma,MPATH: 549 - carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-817|1|875|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-818|1|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-819|1|891|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-820|1|366|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-821|1|926|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-822|1|665|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-823|1|673|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-824|1|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-825|1|810|Neoplasia malignant|Integumentary system|SC basal cell carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-826|1|837|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-827|1|864|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-828|1|870|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-829|1|905|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-970|1|462|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-971|1|860|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-972|1|486|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-973|1|641|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-975|1|678|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenocarcinoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-976|1|693|Neoplasia unclassified|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|Adrenal tumor,MPATH: 218 - neoplasm|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-977|1|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-978|1|753|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-979|1|817|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-980|1|824|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-981|1|640|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-982|1|838|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-983|1|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-984|1|705|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Liv fatty degeneration,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-985|1|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-986|1|779|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-987|1|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-988|1|797|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-989|1|807|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-990|1|813|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1100|1|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1101|1|727|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1102|1|734|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1103|1|811|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1104|1|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1106|1|827|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1107|1|881|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1108|1|921|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1109|1|692|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1110|1|713|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1112|1|777|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1113|1|804|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1116|1|874|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1117|1|885|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1118|1|970|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1119|1|971|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1120|1|974|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1121|1|669|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1122|1|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1124|1|762|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1126|1|810|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1128|1|845|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1129|1|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1130|1|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1132|1|934|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1133|1|674|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1134|1|991|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1135|1|785|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1137|1|799|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Abdominal adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1138|1|800|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1139|1|812|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1140|1|827|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenocarcinoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1142|1|841|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1144|1|903|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1145|1|927|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1147|1|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1148|1|928|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1149|1|656|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1151|1|722|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1152|1|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1155|1|854|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1156|1|884|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|St.squamous cell carcinoma,MPATH: 549 - carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1157|1|889|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1158|1|921|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1160|1|926|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1162|1|854|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1163|1|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1166|1|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1167|1|946|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1169|1|972|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1170|1|750|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1171|1|963|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1172|1|777|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1173|1|789|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1174|1|795|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Abdominal tumor,MPATH: 218 - neoplasm|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1175|1|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1176|1|871|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1177|1|889|Neoplasia benign|Other local manifestations and miscellaneus|SC myxoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1178|1|894|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-1|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|128 (128 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-1-1179|1|952|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-503|2|339|Neoplasia benign|Bone among musculo-skeletal system diseases|local osteoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-504|2|867|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-505|2|461|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-506|2|626|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-507|2|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-508|2|661|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv fatty degeneration,MPATH: 551 - sarcoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-509|2|740|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-510|2|752|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.fibroadenocarcinoma,MPATH: 549 - carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-511|2|818|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-513|2|852|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-514|2|444|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-515|2|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-516|2|528|Other deterministic changes|Bone among musculo-skeletal system diseases|Pulm.septal fibrosis|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-517|2|538|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-518|2|585|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-520|2|670|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty deg./Ut.endometritis|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-521|2|773|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-522|2|804|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma\Ut.endometritis,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-524|2|844|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-525|2|871|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary sarcoma,MPATH: 551 - sarcoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-563|2|549|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-564|2|591|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus tumor,MPATH: 218 - neoplasm|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-565|2|654|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-566|2|815|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-567|2|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-568|2|836|Neoplasia benign|Lower respiratory system|Pulm.adenoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-569|2|836|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-570|2|850|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-571|2|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-572|2|563|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-573|2|565|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty deg. & fibrosis|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-574|2|565|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-575|2|565|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-576|2|675|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-577|2|745|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-578|2|811|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid int.lym.inflt|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-579|2|850|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-580|2|883|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-581|2|647|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-582|2|890|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid int.lym.inflt|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-583|2|773|Other deterministic changes|Bone among musculo-skeletal system diseases|Ut.endometritis|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-584|2|778|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-585|2|780|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-586|2|787|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Liv cirrhosis & fatty deg.|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-587|2|790|Other deterministic changes|Bone among musculo-skeletal system diseases|Pneumonitis with fibrosis|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-588|2|859|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|Kidney adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-589|2|861|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-2|n/a,n/a|1|90|Pu-239 citrate|10|becquerels|Injection, intraperitoneal|0.067 ± 0.01 Gy skeletal dose|48 (48 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-2-1790|2|679|n/a|n/a|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-528|3|458|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-529|3|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma\SalGl fibrosis,MPATH: 268 - adenocarcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-530|3|577|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-531|3|689|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-532|3|703|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-533|3|747|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv deg./Sp fibrosis|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-535|3|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-536|3|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-538|3|868|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-539|3|883|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-540|3|650|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|St.squamous cell carcinoma,MPATH: 549 - carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-541|3|869|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus tumor\Liv fatty droplets,MPATH: 218 - neoplasm|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-542|3|684|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-543|3|696|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-544|3|738|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-545|3|801|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-546|3|824|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.fibroadenocarcinoma,MPATH: 549 - carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-547|3|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-549|3|839|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-550|3|857|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-551|3|732|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor\Liv necrosis & lym.inflt|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-552|3|885|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-553|3|769|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-555|3|776|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-556|3|777|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenocarcinoma\Liv degeneration,MPATH: 277 - cystadenoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-557|3|781|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-558|3|781|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-559|3|788|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-560|3|789|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-562|3|874|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-590|3|395|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-591|3|840|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-592|3|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Splenic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-593|3|689|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-594|3|703|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-595|3|710|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-596|3|724|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-598|3|789|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-599|3|791|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus tumor,MPATH: 218 - neoplasm|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-600|3|832|Other deterministic changes|Bone among musculo-skeletal system diseases|Glomerulonephritis|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-601|3|137|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-602|3|933|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-603|3|284|Other deterministic changes|Bone among musculo-skeletal system diseases|Pulm.mineralization|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-604|3|514|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-605|3|675|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|St.carcinoma,MPATH: 549 - carcinoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-606|3|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-607|3|752|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Liv fatty degeneration,MPATH: 277 - cystadenoma|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-608|3|797|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-609|3|801|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Pulm.cyst.emphysema/Kid urinary casts|
2001-8-3|n/a,n/a|1|90|Pu-239 citrate|110|becquerels|Injection, intraperitoneal|0.693 ± 0.115 Gy skeletal dose|50 (50 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-3-610|3|851|Neoplasia benign|Lower respiratory system|Pulm.adenoma\Liv lym.& PC inflt|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-411|4|470|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-412|4|661|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-413|4|470|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Dermal alopecia|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-414|4|508|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-415|4|543|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv centrilob.vacuolar degeneration|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-417|4|559|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv micro.necrosis|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-418|4|586|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-419|4|622|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic Lymphoma\Pulm granuloma,MPATH: 513 - Lymphoid neoplasms|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-420|4|638|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv micro.granuloma/Kid int.PMN/BM fibr.|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-421|4|651|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-450|4|294|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-451|4|661|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-452|4|310|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-453|4|494|Other deterministic changes|Bone among musculo-skeletal system diseases|SalGl lym.inflt/anemia|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-454|4|538|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Kid tubular hyalinization & eosin.granules|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-455|4|540|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-457|4|591|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Int.nephritis & urinary casts|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-458|4|602|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Kid hydrotubule/Pan.int.lym.inflt|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-459|4|640|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-460|4|654|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-491|4|311|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv embolism|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-492|4|680|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Liv granuloma,MPATH: 277 - cystadenoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-493|4|688|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Liv granuloma,MPATH: 277 - cystadenoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-494|4|389|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-495|4|447|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-496|4|475|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-498|4|495|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma\Pulm.granuloma,MPATH: 513 - Lymphoid neoplasms|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-499|4|532|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-500|4|532|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty & ves. deg./Kid glomer. atrophy|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-501|4|564|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-4|n/a,n/a|1|90|Pu-239 citrate|522|becquerels|Injection, intraperitoneal|between 500 and 1000 Bq 4.66 ± 0.68 Gy skeletal dose|31 (31 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-4-502|4|581|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-401|5|290|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-402|5|605|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-403|5|344|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-404|5|369|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-405|5|416|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-406|5|432|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-407|5|433|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-408|5|461|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-409|5|536|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-410|5|556|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv perichollangiol. lym.inflt/interst.nephritis|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-439|5|322|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty Liver/Glomerular atrophy|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-440|5|583|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Cholangiocarcinoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-442|5|322|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty Liver/Glomerular atrophy|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-443|5|338|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-444|5|396|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-445|5|406|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-446|5|416|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-447|5|416|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-448|5|437|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-449|5|523|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-481|5|332|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Interst.pancreatitis|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-482|5|525|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-483|5|340|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-484|5|387|Other deterministic changes|Bone among musculo-skeletal system diseases|Pyelonephritis|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-485|5|432|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-486|5|447|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv vacuol.vesicul.deg. & peicholla.fibr./Pan.L'islets atrophy/SalGl interst.lym.inflt|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-487|5|452|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Pan.int.fibrosis & lym.inflt..|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-488|5|517|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-489|5|525|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-5|n/a,n/a|1|90|Pu-239 citrate|727|becquerels|Injection, intraperitoneal|between 1000 and 5000 Bq 6.92 ± 0.67 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-5-490|5|525|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-392|6|190|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-393|6|253|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-394|6|300|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-395|6|315|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-396|6|349|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-397|6|365|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-398|6|365|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-399|6|375|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-400|6|427|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-431|6|300|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma\Liv fatty droplets,MPATH: 513 - Lymphoid neoplasms|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-432|6|314|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-433|6|330|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-434|6|338|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-435|6|355|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-436|6|356|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-437|6|406|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-438|6|441|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-471|6|284|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-472|6|452|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-473|6|297|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv dissem. fatty degeneration|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-474|6|311|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv perilob.fatty degeneration|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-475|6|339|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-476|6|374|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-477|6|383|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty Liver|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-478|6|416|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-479|6|416|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-6|n/a,n/a|1|90|Pu-239 citrate|1030|becquerels|Injection, intraperitoneal|between 5000 and 10000 Bq 25,5 ± 3.7 Gy skeletal dose|27 (27 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-6-480|6|416|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-322|7|220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-323|7|438|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-344|7|250|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-365|7|270|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Malignant histiocytoma,MPATH: 409 - fibrous histiocytoma|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-386|7|360|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-387|7|383|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-388|7|383|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-389|7|386|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-390|7|406|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-391|7|438|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv micro.necrosis/Kid urinary casts|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-422|7|256|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-423|7|330|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Splenic lymphoma\Liv fatty droplets,MPATH: 513 - Lymphoid neoplasms|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-424|7|338|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Intestinal lymphoma\,MPATH: 513 - Lymphoid neoplasms|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-425|7|355|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-426|7|360|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-427|7|388|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-428|7|398|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets/fibrous adhesive abd.organs|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-429|7|466|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-430|7|468|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-461|7|233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma\Liv fatty droplets,MPATH: 513 - Lymphoid neoplasms|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-462|7|452|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv degeneration|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-463|7|254|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-464|7|341|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-465|7|367|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-466|7|377|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-467|7|381|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-468|7|402|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-469|7|430|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial fibrosis|
2001-8-7|n/a,n/a|1|90|Pu-239 citrate|11000|becquerels|Injection, intraperitoneal|42.4 ± 2.8 Gy skeletal dose0 Gy skeletal dose|29 (29 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-7-470|7|441|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-611|8|720|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Kid glomerul. hyaliniz./Liv fatty deg. & necro.|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-612|8|938|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma,MPATH: 277 - cystadenoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-613|8|721|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-614|8|754|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Rib bone fibrosarcom\Liv pericholangiolar lym.inflt,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-615|8|791|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-616|8|802|Neoplasia unclassified|Ovary among reproductive system diseases|Granulosa cell tumor|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-619|8|825|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-621|8|830|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-622|8|845|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-623|8|908|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-624|8|710|Neoplasia benign|Bone among musculo-skeletal system diseases|local.osteoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-625|8|952|Neoplasia malignant|Bloodvessels among cardiovascular system|Hemangiosarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-627|8|739|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-628|8|741|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma\Kid interstitial nephritis|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-630|8|768|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Kid interst.lym.inflt,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-631|8|777|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv focal necrosis|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-632|8|778|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Fibrosarcoma,MPATH: 408 - soft tissue fibrosarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-633|8|781|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv fatty degeneration|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-634|8|800|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-636|8|933|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-637|8|651|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-639|8|942|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-640|8|653|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-641|8|771|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-643|8|775|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|ovarial carcinoma\Liv centrilobular focal necrosis,MPATH: 549 - carcinoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-644|8|865|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-645|8|866|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-646|8|866|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv interst.perivas.lym.inflt/Kid int.lym.inflt,MPATH: 551 - sarcoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-647|8|867|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-8|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.68 ± 0.08 Gy skeletal dose Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-8-648|8|890|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-778|9|455|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-779|9|669|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-780|9|475|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-781|9|532|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-782|9|571|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-783|9|574|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-784|9|577|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-785|9|609|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-786|9|627|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-787|9|632|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-788|9|527|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-789|9|854|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-790|9|531|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-791|9|566|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-792|9|576|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-793|9|580|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-794|9|670|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-795|9|677|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-797|9|698|Neoplasia benign|Lower respiratory system|Pulm.adenoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-798|9|825|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-799|9|413|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-800|9|739|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-801|9|423|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-802|9|443|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-803|9|501|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-804|9|531|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-805|9|576|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-806|9|585|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-807|9|648|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-9|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.71 ± 0.35 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-9-808|9|679|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-940|10|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-941|10|575|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-942|10|347|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-943|10|408|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-944|10|467|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|Giant cell osteosarcoma,MPATH: 551 - sarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-945|10|479|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-946|10|485|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-947|10|499|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-948|10|521|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-949|10|529|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-950|10|375|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-951|10|512|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-952|10|528|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-953|10|402|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-954|10|413|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-955|10|434|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-956|10|472|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-957|10|480|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-958|10|483|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-959|10|495|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-960|10|511|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-961|10|259|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-962|10|405|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-963|10|406|Neoplasia benign|Bone among musculo-skeletal system diseases|local.osteoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-964|10|425|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-965|10|440|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-966|10|444|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-967|10|445|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-968|10|448|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-10|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.42 ± 0.57 Gy skeletal dose|30 (30 in ERA)|Mouse|CB3H/He|Female|Young Adult|lifespan study|2001-8-10-969|10|618|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-286|11|230|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-287|11|367|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-288|11|367|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-289|11|367|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-290|11|276|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-291|11|281|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-292|11|308|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-293|11|325|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-294|11|340|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-295|11|364|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-296|11|366|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-298|11|367|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-299|11|195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma\Liv fatty degeneration,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-300|11|365|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-301|11|397|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-302|11|245|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-303|11|292|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-304|11|294|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-305|11|298|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-306|11|330|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|Giant cell osteosarcoma,MPATH: 551 - sarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-307|11|354|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-308|11|356|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-309|11|356|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|v,MPATH: 551 - sarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-310|11|160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leuk.Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-311|11|276|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-312|11|276|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-313|11|276|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-314|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-315|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-316|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-317|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-318|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-319|11|179|Other deterministic changes|Bone among musculo-skeletal system diseases|BM fibrosis|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-320|11|199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-321|11|266|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-324|11|237|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-325|11|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-326|11|237|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-327|11|237|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-328|11|279|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-329|11|297|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-330|11|298|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-331|11|333|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-332|11|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-333|11|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-334|11|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-335|11|429|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-336|11|252|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-337|11|276|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-338|11|290|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-339|11|293|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-340|11|335|Neoplasia benign|Bone among musculo-skeletal system diseases|local.osteoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-341|11|348|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-342|11|362|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-11|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|16.3 ± 2.2 Gy skeletal dose|55 (55 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-11-343|11|362|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid interst.mononuclear inflt|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-1|12|217|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-2|12|220|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-3|12|222|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-4|12|225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-5|12|261|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty Liver|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-6|12|269|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration & focal necrosis|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-7|12|270|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-8|12|270|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-9|12|274|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-10|12|283|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-11|12|290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-12|12|298|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-13|12|305|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty deg./Kid hydronephrosis & fibrosis|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-14|12|321|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-15|12|321|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-16|12|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-17|12|343|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-18|12|375|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-19|12|407|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-20|12|423|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-21|12|423|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-22|12|443|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-12|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|32.2 ± 5.8Gy skeletal dose|23 (23 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-12-23|12|731|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-91|13|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-92|13|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-93|13|644|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-94|13|648|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv lym.inflt/Lg perivas. lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-95|13|649|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid pelvic interst.lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-96|13|652|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg alveolar eosinophilic deposits|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-97|13|727|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC\Kid urinary casts|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-98|13|799|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC\Kid fibrous scar/Liv necrosis & fatty deg.|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-99|13|802|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-701|13|383|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-702|13|984|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-703|13|528|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-704|13|583|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-705|13|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|local.lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-706|13|802|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-707|13|803|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty droplets & int.perivas.lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-708|13|912|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-709|13|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-710|13|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-711|13|402|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-712|13|959|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-713|13|601|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-714|13|625|Other deterministic changes|Bone among musculo-skeletal system diseases|Ht coronary fibrous thickening|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-715|13|734|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty liver|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-716|13|789|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-717|13|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|T-cell.lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-718|13|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-719|13|932|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-720|13|940|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-862|13|616|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-863|13|885|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Liv fatty degeneration|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-864|13|638|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-865|13|658|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-866|13|667|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-868|13|668|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-869|13|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-870|13|678|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Liv fatty degeneration|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-871|13|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-872|13|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-873|13|533|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-874|13|833|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv sinusoidal & interstitial lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-875|13|641|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv sinusoid.mononuclear & perivas.lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-876|13|641|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Abdominal lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-877|13|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lLymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-878|13|748|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg alveolar eosinophilic deposits|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-879|13|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic lymphoma\Lg alveolar eosinophilic deposits,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-880|13|795|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg alveolar eosinophilic deposits|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-881|13|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-882|13|829|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg alveolar eosinophilic deposits|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1024|13|390|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1025|13|760|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma,MPATH: 551 - sarcoma|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1026|13|391|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv perivascular lym.inflt|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1027|13|407|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1028|13|412|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1029|13|423|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv sin.perivas.lym.inflt/Lg peribron.lym.prol.|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1030|13|443|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1031|13|489|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv perivascul.lym.inflt/Lg peribronch.lym.gr.|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1032|13|515|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1033|13|625|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1034|13|352|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1035|13|839|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1036|13|382|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1037|13|397|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1038|13|419|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1039|13|449|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid glomerular hyalinization|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1040|13|621|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1041|13|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1042|13|726|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-13|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|Gy skeletal dose|69 (69 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-13-1043|13|809|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-670|14|653|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-671|14|917|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg hemorrhage, edema & alveolar eosino.dep.|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-672|14|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-673|14|681|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma\Lg & Kid interst.lym.inflt|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-674|14|722|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-675|14|724|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-676|14|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-677|14|764|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv chollangiolar proliferation|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-678|14|807|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv sinusoid & perivascular mononuclear inflt|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-679|14|852|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-680|14|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-681|14|924|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-682|14|611|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-683|14|655|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid interst.perivascul.lym.inflt|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-684|14|703|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv necrotizing hepatitis|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-685|14|704|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-686|14|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-687|14|822|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv micronecrosis & sin.mononuclear inflt|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-688|14|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-689|14|881|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-690|14|480|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-691|14|782|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv interst.lym.inflt & fibrosis|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-692|14|594|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-693|14|615|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-694|14|669|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv focal necrosis|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-695|14|712|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-696|14|717|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv promyel.inflt/Lg alveol. eosinophil. sub.|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-698|14|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-699|14|761|Neoplasia malignant|Other local manifestations and miscellaneus|Abdominal sarcoma|
2001-8-14|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.62 ± 0.063 Gy skeletal dose|30 (30 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-14-700|14|766|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-830|15|435|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|local.lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-831|15|720|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-832|15|500|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-833|15|549|Neoplasia malignant|Other local manifestations and miscellaneus|Abdominal sarcoma\SalGl interstitial lym.inflt|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-834|15|593|Neoplasia benign|Bone among musculo-skeletal system diseases|local.osteoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-835|15|622|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Abdominal lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-836|15|625|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-837|15|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-838|15|682|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-839|15|701|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-840|15|364|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma\Kid glomerular hyalinization,MPATH: 268 - adenocarcinoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-841|15|536|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-842|15|573|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-844|15|610|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-845|15|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-846|15|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-847|15|684|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.fibroadenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-848|15|744|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid & Lg perivascular lym.inflt|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-849|15|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-850|15|237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-851|15|625|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-852|15|646|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-853|15|677|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-854|15|442|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-855|15|471|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-856|15|487|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Kid pelvic interst.lym.inflt|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-857|15|507|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-858|15|509|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|local.osteofibrosarcoma\Liv necrotizing hepatitis,MPATH: 551 - sarcoma|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-859|15|519|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-860|15|525|Neoplasia malignant|Liver among hepato-pancreatic system diseases|nodular hepatocellular Ca\Liv fatty degeneration|
2001-8-15|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.66 ±0.43 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-15-861|15|623|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-992|16|252|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-993|16|442|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-994|16|293|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-995|16|339|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-996|16|369|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Stomach lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-997|16|378|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-998|16|385|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-999|16|405|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1000|16|408|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1001|16|440|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1002|16|300|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1003|16|597|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1004|16|304|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1005|16|353|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1006|16|363|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1007|16|369|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1008|16|371|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1009|16|373|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1010|16|454|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1011|16|521|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1012|16|348|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1013|16|551|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1014|16|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1015|16|573|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1016|16|355|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Kid interstitial nephritis|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1017|16|386|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1018|16|411|Neoplasia malignant|Bone among musculo-skeletal system diseases|OsteosarcomaLiv perivasc.lym.inflt/Kid glomerular hyaliniz.|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1019|16|413|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1020|16|442|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1021|16|466|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|Giant cell osteosarcoma,MPATH: 551 - sarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1022|16|471|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-16|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.08 ± 0.67 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|Young Adult|lifespan study|2001-8-16-1023|16|500|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-345|17|238|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-346|17|465|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-347|17|238|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-348|17|238|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-349|17|283|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-350|17|307|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-351|17|334|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-352|17|334|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-353|17|334|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-354|17|384|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|local.osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-355|17|300|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-356|17|691|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-357|17|323|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-358|17|357|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-359|17|363|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-360|17|373|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Kid cyst|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-361|17|378|Neoplasia benign|Bone among musculo-skeletal system diseases|local osteoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-362|17|386|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-363|17|390|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-17|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|17.4 ±3.5 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-17-364|17|434|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-24|18|294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma\Liv fatty degeneration,MPATH: 513 - Lymphoid neoplasms|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-25|18|328|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-26|18|336|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-27|18|340|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-28|18|354|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-29|18|368|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-30|18|372|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-31|18|379|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-32|18|381|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv fatty degeneration|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-33|18|406|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma,MPATH: 551 - sarcoma|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-34|18|412|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-35|18|416|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-36|18|433|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-37|18|444|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-38|18|446|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-39|18|448|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-40|18|476|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-41|18|476|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-42|18|481|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-43|18|487|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-44|18|487|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-45|18|488|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-46|18|507|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-47|18|509|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-48|18|578|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Kid hydronephrosis|
2001-8-18|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.9 - 45.0 Gy skeletal dose|26 (26 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-18-49|18|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-100|19|569|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|MAC\Liv focal degeneration & necrosis,MPATH: 268 - adenocarcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-101|19|740|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia\Liv centrilobular necrosis|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-102|19|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-103|19|762|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-104|19|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-105|19|817|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-106|19|835|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-107|19|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|T-Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-108|19|838|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid pelvic lym.infl|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-756|19|530|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-757|19|980|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-758|19|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-759|19|595|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-760|19|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-761|19|674|Neoplasia malignant|Liver among hepato-pancreatic system diseases|local hepatocelular Ca|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-762|19|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-763|19|815|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty deg./Lg perivascular lym.inflt|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-764|19|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-765|19|897|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid interstitial lym.inflt|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-766|19|671|Other deterministic changes|Bone among musculo-skeletal system diseases|Ut endometritis/chyloperitoneum|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-767|19|1003|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-768|19|731|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-770|19|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-771|19|759|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-772|19|827|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-774|19|854|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-775|19|891|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-776|19|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-777|19|928|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Abdominal tumor,MPATH: 218 - neoplasm|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-919|19|529|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-920|19|994|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-921|19|665|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-922|19|724|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-923|19|731|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-924|19|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-925|19|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-926|19|757|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-927|19|816|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-928|19|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Lg alveolar eosinophilic deposits,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-929|19|329|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-930|19|1026|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-931|19|521|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibroadenocarcinoma,MPATH: 551 - sarcoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-932|19|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-933|19|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-934|19|749|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-936|19|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-937|19|893|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv centrilobular necrosis & fatty deg.|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-938|19|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-19|n/a,n/a|1|90|none (controls)|0|becquerels|Injection, intraperitoneal|n/a|49 (49 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-19-939|19|1014|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-721|20|614|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid & Lg perivascular lymphoid inflt|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-722|20|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-724|20|620|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-725|20|642|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-726|20|649|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv sinusoid PMNs & interst.lym.inflt,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-727|20|696|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-728|20|780|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-730|20|795|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-731|20|856|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv interst.perivascular mononuclear inflt|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-732|20|867|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-733|20|602|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-734|20|632|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-735|20|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|local.lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-736|20|667|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-738|20|692|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-740|20|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-741|20|819|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-742|20|857|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-743|20|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-744|20|511|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-745|20|792|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|Osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-746|20|822|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\Fatty Liver,MPATH: 268 - adenocarcinoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-747|20|835|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-748|20|596|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-749|20|639|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv perivascular lym.inflt|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-750|20|699|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv sinsoid PMNs/Kid & Lg int.fibrosis,MPATH: 551 - sarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-751|20|704|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Liv int.lym.inflt/Kid subcapsular fibrosis,MPATH: 277 - cystadenoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-752|20|711|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-753|20|715|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-754|20|725|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma\Liv focal necrosis|
2001-8-20|n/a,n/a|1|90|Pu-239 citrate|100|becquerels|Injection, intraperitoneal|0.63 ± 0.064 Gy skeletal dose|31 (31 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-20-755|20|728|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-883|21|414|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-884|21|831|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-885|21|454|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-886|21|477|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-887|21|487|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-888|21|507|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-889|21|523|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-890|21|604|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-891|21|641|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|Giant cell osteosarcoma\Liv fatty droplets & Pitt cells,MPATH: 551 - sarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-892|21|682|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid pelvic interstitial mononuclear inflt|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-893|21|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-894|21|1016|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-895|21|519|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-896|21|527|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-897|21|535|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-898|21|540|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-899|21|566|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-901|21|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulm.adenocarcinoma\Kid glomerular swelling & hyalinization,MPATH: 268 - adenocarcinoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-902|21|647|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-903|21|679|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-904|21|420|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg bronchial papillary gr/BM fat dep|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-905|21|580|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.sarcoma,MPATH: 551 - sarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-906|21|590|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-907|21|608|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-908|21|647|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-909|21|481|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-910|21|500|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-911|21|505|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-912|21|521|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-914|21|523|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-915|21|530|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-917|21|544|Neoplasia benign|Bone among musculo-skeletal system diseases|local.osteoma\Lg perivascular lym.inflt|
2001-8-21|n/a,n/a|1|90|Pu-239 citrate|500|becquerels|Injection, intraperitoneal|2.62 ± 0.37 Gy skeletal dose|33 (33 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-21-918|21|579|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1044|22|331|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty deg./Kid glomerulonephritis|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1045|22|528|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Liv fatty degeneration|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1046|22|567|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1047|22|380|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma\Kid pelvic interst.lym.inflt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1048|22|383|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1049|22|396|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid interst. & Sp subcapsular amyloidosis|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1050|22|397|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1051|22|405|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1052|22|415|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1053|22|438|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1054|22|466|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1055|22|376|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1056|22|546|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1057|22|574|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Liv focal necrosis/Kid interst.lym.inflt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1059|22|377|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid pelvic interst.lym.inflt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1060|22|401|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1061|22|416|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv interst.perivasc.mononuclear inflt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1062|22|432|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1063|22|440|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1064|22|450|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1065|22|499|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1066|22|505|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1067|22|398|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid pelvic interst.lym.infilt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1068|22|537|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1069|22|571|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1070|22|399|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1071|22|401|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1072|22|424|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1073|22|446|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1074|22|451|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1075|22|470|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma\Kid pelvic interst.perivascilar lym.inflt|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1076|22|481|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1077|22|532|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1078|22|370|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1079|22|892|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1080|22|453|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Fatty Liver,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1081|22|576|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1082|22|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1083|22|627|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1084|22|733|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1085|22|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1086|22|859|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Kid glomerular hyalinization,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1087|22|883|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1088|22|560|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1089|22|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1090|22|606|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1091|22|654|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1092|22|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1093|22|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1094|22|677|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1096|22|782|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1097|22|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-22|n/a,n/a|1|90|Pu-239 citrate|1000|becquerels|Injection, intraperitoneal|4.38 ± 0.50 Gy skeletal dose|53 (53 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-22-1098|22|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-366|23|215|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-367|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-368|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-369|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-370|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-371|23|313|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-372|23|330|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-373|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-374|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-375|23|239|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-376|23|280|Neoplasia malignant|Bone among musculo-skeletal system diseases|local.osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-377|23|397|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-378|23|304|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-379|23|319|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-380|23|320|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-381|23|329|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-382|23|338|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-383|23|353|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-384|23|354|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-23|n/a,n/a|1|90|Pu-239 citrate|5000|becquerels|Injection, intraperitoneal|15.4 ± 3.2 Gy skeletal dose|20 (20 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-23-385|23|366|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-50|24|180|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-51|24|202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-52|24|291|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-53|24|314|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC squamous cell carcinoma,MPATH: 446 - squamous cell carcinoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-54|24|340|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty degeneration|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-55|24|349|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv fatty & vesicular degeneration|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-56|24|352|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-57|24|369|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-58|24|371|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-59|24|375|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-60|24|384|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-61|24|386|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-62|24|403|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-63|24|414|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-64|24|419|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-65|24|425|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-66|24|433|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-67|24|434|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-68|24|444|Other deterministic changes|Bone among musculo-skeletal system diseases|Sp Gamna-Gandy body|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-69|24|446|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-70|24|453|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-71|24|461|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-72|24|471|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-73|24|473|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-74|24|480|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv lym.inflt & fibrosis|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-75|24|516|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Kid hydronephrosis,MPATH: 551 - sarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-76|24|537|Neoplasia benign|Bone among musculo-skeletal system diseases|Osteoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-77|24|538|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid hydronephrosis|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-78|24|539|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-79|24|558|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv lym.inflt/Kid hydronephrosis|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-80|24|571|Neoplasia benign|Bone among musculo-skeletal system diseases|microscopic osteoma|
2001-8-24|n/a,n/a|1|90|Pu-239 citrate|10000|becquerels|Injection, intraperitoneal|41.5 ±  7.9 Gy skeletal dose|32 (32 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-24-81|24|573|Other deterministic changes|Bone among musculo-skeletal system diseases|Sp Gandy-Gamna body|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-109|25|141|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-110|25|156|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-111|25|160|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-112|25|166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-113|25|171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-114|25|176|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-115|25|178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-116|25|178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-117|25|181|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-118|25|186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-119|25|196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-120|25|200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-121|25|205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-122|25|205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoid leukemia,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-123|25|209|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-124|25|210|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-125|25|219|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-126|25|227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-127|25|233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-128|25|256|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-129|25|266|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-130|25|284|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-131|25|295|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-132|25|317|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-133|25|333|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-134|25|351|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-135|25|355|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|Stomach SCC,MPATH: 549 - carcinoma|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-136|25|374|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-137|25|390|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-193|25|132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-194|25|141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-195|25|143|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-196|25|149|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-197|25|149|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-198|25|151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-199|25|151|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-200|25|155|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-201|25|157|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-202|25|158|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-203|25|159|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-204|25|159|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-205|25|162|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-206|25|162|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-207|25|162|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-208|25|163|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-209|25|164|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-210|25|164|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-211|25|165|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-212|25|165|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-213|25|170|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-214|25|171|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-215|25|172|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-216|25|173|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-217|25|173|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-218|25|175|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-219|25|175|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-220|25|175|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-221|25|176|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-222|25|176|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-25|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-25-223|25|176|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-138|26|132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-139|26|134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-140|26|141|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-141|26|141|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-142|26|141|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-143|26|143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-144|26|143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-145|26|144|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-146|26|146|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-147|26|146|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-148|26|152|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-149|26|153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphomaThymic lymphomaThymic lymphoma\,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-150|26|154|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-151|26|155|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-152|26|159|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-153|26|159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphomaThymic lymphomaThymic lymphoma\,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-154|26|165|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-155|26|166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphomaThymic lymphomaThymic lymphoma\,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-156|26|167|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-157|26|170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-158|26|170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-159|26|173|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-160|26|173|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-224|26|107|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-225|26|116|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-226|26|132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-227|26|141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-228|26|144|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-229|26|146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-230|26|146|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-231|26|148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-232|26|148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-233|26|148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-234|26|150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-235|26|150|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-236|26|151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-237|26|152|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-238|26|153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-239|26|153|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-240|26|153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-241|26|155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-242|26|157|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-243|26|158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-244|26|159|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-245|26|160|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-246|26|161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-247|26|163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-248|26|163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-249|26|166|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-250|26|168|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-251|26|168|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-252|26|169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-253|26|170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-26|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|54 (54 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-26-254|26|170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-161|27|121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-162|27|127|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-163|27|129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-164|27|138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-165|27|141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-166|27|143|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-167|27|145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-168|27|148|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-169|27|151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-170|27|151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-171|27|155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-172|27|157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-173|27|158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-174|27|159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-175|27|160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-176|27|166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-177|27|169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-178|27|172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-179|27|172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-180|27|175|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-181|27|180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-182|27|183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-183|27|184|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-184|27|185|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-185|27|186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-186|27|188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-187|27|192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-188|27|194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-189|27|194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-190|27|198|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-191|27|208|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-192|27|220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-255|27|148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-256|27|159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-257|27|159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-258|27|164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-259|27|169|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-260|27|170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-261|27|171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-262|27|172|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-263|27|173|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-264|27|176|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-265|27|178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-266|27|178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-267|27|178|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-268|27|178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-269|27|180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-270|27|183|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-271|27|185|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-272|27|185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-273|27|194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-274|27|196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-275|27|196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-276|27|201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-277|27|204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-278|27|216|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-279|27|224|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-280|27|233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-281|27|238|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-282|27|289|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-283|27|318|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-284|27|355|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-27|n/a,n/a|1|91|Nmethyl N-nitrosourea (MNU)|5|milligrams per animal|Injection, intraperitoneal|divided in 5 weekly injections 40 mg/kg|63 (63 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-27-285|27|488|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|Lung adenoma,MPATH: 270 - adenoma|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1180|28|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LBL),MPATH: 513 - Lymphoid neoplasms|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1181|28|774|Other deterministic changes|Bone among musculo-skeletal system diseases|Brain demyelination|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1182|28|809|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1183|28|825|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1184|28|855|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1185|28|855|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1186|28|858|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial fibrosis|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1187|28|858|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1188|28|859|Other deterministic changes|Bone among musculo-skeletal system diseases|Spinal demyelination ?|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1189|28|904|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty degeneration|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1190|28|907|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1191|28|928|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1192|28|763|Other deterministic changes|Bone among musculo-skeletal system diseases|Heart cardiomuscular fibrosis|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1193|28|820|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan.islet hypetrophy|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1194|28|890|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocarditis|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1195|28|902|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1196|28|908|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\Bone trabecular bone prolifer.,MPATH: 268 - adenocarcinoma|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1197|28|915|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1198|28|915|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1199|28|921|Neoplasia unclassified|Liver among hepato-pancreatic system diseases|Liver tumor\Liv.nod.hyperplasia/Pan.int.lym.inflt./Kid.Ca depo|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1200|28|949|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1201|28|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1202|28|951|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-28|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-28-1203|28|951|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC Carcinoma,MPATH: 446 - squamous cell carcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1252|29|541|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1253|29|606|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1254|29|636|Other deterministic changes|Bone among musculo-skeletal system diseases|Atrophy/lung hyperemia/spinal deg. & demyelin.|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1255|29|655|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor\Atrophy without nervous lesions,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1256|29|669|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus sarcoma\Skeletal osteopetrotic trabeculare,MPATH: 551 - sarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1257|29|672|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.cystadenoma\Kid.urinary cyst,MPATH: 277 - cystadenoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1258|29|753|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1259|29|788|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SCFS,MPATH: 551 - sarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1260|29|802|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1261|29|811|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glomerul.atrophy & urinary casts|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1262|29|816|Other deterministic changes|Bone among musculo-skeletal system diseases|Trabecular bone growth & BM fibrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1263|29|823|Other deterministic changes|Bone among musculo-skeletal system diseases|Sp.necrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1264|29|823|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan.islet slight hypertrophy|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1265|29|825|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1266|29|834|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial fibrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1267|29|839|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1268|29|841|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1269|29|847|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1270|29|848|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1271|29|851|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1272|29|851|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1273|29|851|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1274|29|853|Other deterministic changes|Bone among musculo-skeletal system diseases|BM fibrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1275|29|853|Neoplasia benign|Liver among hepato-pancreatic system diseases|HCAD\Kid.infarct & int.lym.inflt.|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1276|29|858|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1277|29|858|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1278|29|921|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1279|29|924|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1280|29|924|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|MAD,MPATH: 266 - fibroadenoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1281|29|942|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1520|29|622|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma(T-LBL),MPATH: 513 - Lymphoid neoplasms|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1521|29|634|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1522|29|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LBL)\Heart edema,MPATH: 513 - Lymphoid neoplasms|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1523|29|712|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1524|29|718|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor\Liv.sinusoidal enlargement,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1525|29|721|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1526|29|732|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1527|29|743|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1528|29|745|Neoplasia unclassified|Ovary among reproductive system diseases|Ovary granulosa cell tumor\Cardiomuscular fibrosis/BM fibrosis & tr.bone grow|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1529|29|757|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1530|29|769|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1531|29|774|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Trabecular bone gr. & BM fibrosis,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1532|29|781|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1533|29|795|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1534|29|806|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1535|29|811|Other deterministic changes|Bone among musculo-skeletal system diseases|BM fibrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1536|29|815|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1537|29|820|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1538|29|837|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1539|29|853|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1540|29|860|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial fibrosis|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1541|29|865|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1542|29|886|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1543|29|893|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1544|29|900|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1545|29|907|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1546|29|914|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1547|29|957|Other deterministic changes|Bone among musculo-skeletal system diseases|Adr.MN & round/ovoid cells|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1548|29|965|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial PMN inflt.|
2001-8-29|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-29-1549|29|965|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1282|30|539|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1283|30|574|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1284|30|603|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1285|30|610|Other deterministic changes|Bone among musculo-skeletal system diseases|Atrophy|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1286|30|638|Other deterministic changes|Bone among musculo-skeletal system diseases|Sp.marginal zone amyloidosis|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1287|30|676|Other deterministic changes|Bone among musculo-skeletal system diseases|Atrophy|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1288|30|680|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.Pit & brilliant cells/lung edema/spinal deg.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1289|30|711|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1290|30|714|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor\Pancreas lymphocytic inflt.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1291|30|720|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor\Liv.nod.hyperplasia/Heart pericardial Ca dep.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1292|30|725|Other deterministic changes|Bone among musculo-skeletal system diseases|autolysis|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1293|30|732|Neoplasia malignant|Other local manifestations and miscellaneus|meta.Liposarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1294|30|736|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial calcification|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1295|30|739|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1296|30|753|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Lung hemorrhage & hemosiderin-phagocytes,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1297|30|763|n/a|n/a|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1298|30|782|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|OvCa,MPATH: 549 - carcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1299|30|802|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1300|30|830|Neoplasia malignant|Bloodvessels among cardiovascular system|Hemangiosarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1301|30|832|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg./Pan.islet hypertrophy/BM.trabecul.g|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1302|30|840|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1303|30|851|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan.islet hypertrophy/Tr.bone growth|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1304|30|851|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.regeneration/Kid.infarct|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1305|30|854|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1306|30|855|Other deterministic changes|Bone among musculo-skeletal system diseases|BM trabecular bone growth|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1307|30|862|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.nodular hyperplasia|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1308|30|886|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1309|30|886|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1310|30|886|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1311|30|888|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1550|30|512|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1551|30|518|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1552|30|627|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.nod.hyperplasia/BM hypoplasia & fat-replace.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1553|30|652|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveol.deposition of eosinophilic substances|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1554|30|692|Other deterministic changes|Bone among musculo-skeletal system diseases|Pancreatitis with islets/Glomerulosclerosis with d|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1555|30|699|Other deterministic changes|Bone among musculo-skeletal system diseases|Perivascular lym.inflt.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1556|30|711|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1557|30|713|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.interst.fibrosis & glomerular hyaliniz.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1558|30|713|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|meta.Adrenal carcinoma\Myocardial fibrosis,MPATH: 549 - carcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1559|30|729|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 219 - adnexal and skin appendage tumor|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1560|30|732|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.sinusoidal endothel.proliferation|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1561|30|755|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1562|30|755|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC adenocarcinoma,MPATH: 446 - squamous cell carcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1563|30|767|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1564|30|774|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1565|30|776|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1566|30|789|Other deterministic changes|Bone among musculo-skeletal system diseases|Myocardial necrosis & fibrosis/Trabecular bone pro|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1567|30|795|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1568|30|819|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.necrosis & vascular gr./Myocarditis/Pulm.hemor|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1569|30|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Pan.&Sp.granuloma with giant cells/myocard.fibrosi,MPATH: 513 - Lymphoid neoplasms|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1570|30|824|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1571|30|837|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Abdominal fibrosarcoma,MPATH: 408 - soft tissue fibrosarcoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1572|30|837|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1573|30|848|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor\Liv.fatty degeneration/Sp.G-G body & vas.elongat.|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1574|30|872|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1575|30|883|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1576|30|888|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1577|30|900|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-30|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-30-1578|30|927|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1312|31|372|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung hyperemia/no nervous lesions|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1313|31|316|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoid leukemia,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1314|31|523|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1315|31|343|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1316|31|557|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma,MPATH: 551 - sarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1317|31|501|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1318|31|526|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1319|31|564|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1320|31|564|Neoplasia benign|Bloodvessels among cardiovascular system|Hemangioma\Kidney interst.lymphoid inflt.|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1321|31|581|Other deterministic changes|Bone among musculo-skeletal system diseases|Liver vacuolar & fatty deg.|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1322|31|594|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|focal osteofibrosarcoma,MPATH: 551 - sarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1323|31|609|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Lung hyperremia/myocardial edema|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1324|31|648|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1325|31|662|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor(dysgerminoma)\Liv.necrosis/cardiac arteriolar hyalin. & swelling,MPATH: 316 - mixed germ cell tumor|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1326|31|677|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary adenocarcinoma\Kid.glom.swell./myocard.edemoa & arteriolar swell.,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1327|31|683|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1328|31|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(PreB)\,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1329|31|704|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan.islet atrophy/pericardial fibrosis & mineraliz|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1330|31|711|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1331|31|742|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.slight interst.fibrosis & lym.inflt.|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1332|31|749|Neoplasia malignant|Other local manifestations and miscellaneus|SC liposarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1333|31|766|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1334|31|788|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1335|31|791|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1336|31|802|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Sp.G-G-like body/Lung alv.eosin.crystalline|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1337|31|809|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1338|31|810|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1339|31|839|Other deterministic changes|Bone among musculo-skeletal system diseases|BM trabecular bone growth|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1340|31|851|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|PAD,MPATH: 270 - adenoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1341|31|882|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1579|31|405|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.focal necrosis & abscesses|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1580|31|490|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoid leukemia\Liv.fatty deg.,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1581|31|223|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1582|31|511|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa tumor|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1583|31|554|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphatic Leukemia,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1584|31|563|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta. Osteosarcoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1585|31|575|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1586|31|599|Neoplasia benign|Liver among hepato-pancreatic system diseases|Hep.adenoma\Myocarditis/BM fibrosis|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1587|31|599|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.dysgerminoma,MPATH: 316 - mixed germ cell tumor|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1589|31|620|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1590|31|643|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|Parathyroid adenocarcinoma\,MPATH: 218 - neoplasm|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1591|31|678|Other deterministic changes|Bone among musculo-skeletal system diseases|BM fibrosis|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1592|31|679|Other deterministic changes|Bone among musculo-skeletal system diseases|Panc.islet atrophy|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1593|31|680|Neoplasia malignant|Adrenal gland  among endocrine systems|Adrenal pheochromocytoma\Panc.islet decrease|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1594|31|714|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\BM fibrosis,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1595|31|726|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg. & necrosis|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1596|31|732|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.tumor ?,MPATH: 218 - neoplasm|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1597|31|743|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\Liv.focal necrosis/Sp.necrosis, hematoma,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1598|31|764|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|Adrenal carcinoma,MPATH: 549 - carcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1599|31|767|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1600|31|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1601|31|809|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1602|31|809|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Myocardial edema & slight fibrosis,MPATH: 218 - neoplasm|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1603|31|810|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|meta.Thyroid carcinoma\Pan.islet hypertrophy, lym.inflt./BM trabecular gr,MPATH: 278 - follicular adenocarcinoma|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1604|31|816|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1605|31|816|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1606|31|823|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy & nodular hyperplasia|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1607|31|837|Neoplasia unclassified|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|Adrenal tumor\Liv.fatty deg.& hypertorophy,MPATH: 218 - neoplasm|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1608|31|848|Neoplasia unclassified|Ovary among reproductive system diseases|Ov.granulosa cell tumor|
2001-8-31|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-31-1609|31|879|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1204|32|546|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1205|32|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Kid.glom.hyal. & amyloid dep.,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1206|32|764|Other deterministic changes|Bone among musculo-skeletal system diseases|Pancreas lym.inflt./Kid urinary casts|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1207|32|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Kid.glom.hyal.&mes.increase/Lg.embolism,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1208|32|848|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.hydroneph.glom.hyaliniz./Lg.eosin.crystall.|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1209|32|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Lg.alveolar eosinophilic deposits,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1210|32|882|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveolar eosinophilic crystalline|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1211|32|897|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy/Lg.alveolar eos.crystall.|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1212|32|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Liv.fatty deg.necros./Kid.Bowmans thick.,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1213|32|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1214|32|994|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1215|32|1015|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|Mammary adenoma\Liv.hypertrophy/Kid.lym.inflt./Lg.eos.sub.crystall,MPATH: 266 - fibroadenoma|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1216|32|526|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic (T-) Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1217|32|561|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia\Lg.vascular edema|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1218|32|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1219|32|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1220|32|767|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.mesangial increase & hyalinization|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1221|32|827|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg./Lg.alveolar eos.deposits|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1222|32|837|Other deterministic changes|Bone among musculo-skeletal system diseases|Sp.arteriolar hyalinization|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1223|32|897|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg./Pan.MNC, amyloid/Kid.GNP|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1224|32|902|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1225|32|921|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrous histiocytoma\Liv.fatty deg./Kid.glom.hyal./Eosinophilia,MPATH: 409 - fibrous histiocytoma|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1226|32|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-32|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-32-1227|32|970|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma\Liv.fatty deg. & necros./Lg.alv.eos.sub.& lym.infl,MPATH: 268 - adenocarcinoma|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1342|33|539|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1343|33|652|Neoplasia benign|Liver among hepato-pancreatic system diseases|Hepatic adenoma\Liv.fatty deg./Kid.glomer.hyalin., plasma cell inf|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1344|33|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1345|33|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma\Liv.fatty droplet deg.,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1346|33|701|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.lym.aggr./Kid.int.fibr.&glomer.nephritis|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1347|33|722|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv lym.inflt./Pan islet hypertrophy/Lg.eos.depos.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1348|33|732|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan lym.inflt/Kid glomer.hyal.&mesang.increase|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1349|33|736|Neoplasia benign|Integumentary system,MA: 0000151 - skin|SC fibroma\Pan.int.lym.inflt./Kid.glom.capillary hyalin.lym.i,MPATH: 407 - fibroma|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1350|33|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\autolysis,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1351|33|756|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic substances|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1352|33|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1353|33|777|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|Renal carcinom,MPATH: 549 - carcinoma|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1354|33|777|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline/BM fibrosis|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1355|33|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1356|33|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LCL),MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1357|33|791|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1358|33|808|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1359|33|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty deg./Lung alveolar eosinophilic crystall,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1360|33|826|Neoplasia malignant|Bloodvessels among cardiovascular system|Hemangiosarcoma\Kid.glom.hyaliniz./Alv.eos.crystalline/BM fibrosis|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1361|33|829|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1362|33|841|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.slight eosinophilic crystalline|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1363|33|847|Neoplasia malignant|Bloodvessels among cardiovascular system|meta.Hemangiosarcoma\Pan.int.lym.inflt.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1364|33|847|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor ?,MPATH: 218 - neoplasm|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1365|33|861|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1366|33|875|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveolar eosinophilic depts.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1367|33|882|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1368|33|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1369|33|903|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveolar eosinophilic crystalline|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1370|33|1001|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1371|33|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1610|33|518|Neoplasia malignant|Other local manifestations and miscellaneus|Liposarcoma\Fatty liver|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1611|33|574|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Liv.necrosis & fatty deg./Sp.G-G body|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1612|33|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Kid.glom.hyalin. & subcap.infarct,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1613|33|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1614|33|651|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveol.eosinophilic deposits|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1615|33|653|Neoplasia systemic|Haematolymphatic system|Myeloid(Gr.) leukemia\Kid.glom.hyalin.cap.dilatation|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1616|33|683|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1617|33|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1618|33|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1619|33|714|Other deterministic changes|Bone among musculo-skeletal system diseases|Thyroiditis?|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1620|33|764|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic sub. & phagocytosis|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1621|33|773|Other deterministic changes|Bone among musculo-skeletal system diseases|Panc.islet MNC inflt. & destruction|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1622|33|784|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glom.hyaliniz.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1623|33|792|Neoplasia benign|Liver among hepato-pancreatic system diseases|Hepatocellular adenoma\Myocardial lym.inflt.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1624|33|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Myocardial fibrosis,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1625|33|802|Neoplasia unclassified|Urinary system,MA: 0000380 - urinary bladder|Urinary bladder tumor\Liv.immature granulocyte inflt./hydronephrosis,MPATH: 218 - neoplasm|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1626|33|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Localized lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1627|33|847|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1628|33|847|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1629|33|872|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glom.hyal./Lung alv.eos.deposit.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1630|33|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1631|33|910|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg. & MNC/Kid.glom.hyal. & lym.inflt.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1632|33|917|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1633|33|917|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1634|33|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1635|33|995|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy/Lg.alv.eos.sub. & lym.inflt.|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1636|33|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Liv.necrosis/Lg.alv.eos.sub. & phagocyt.,MPATH: 513 - Lymphoid neoplasms|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1637|33|1001|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alv.eos.crystalline|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1638|33|1002|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg.necr.MNC/Kid.necr.infarct & fibrosis|
2001-8-33|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-33-1639|33|1015|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Liv.MNC inflt./Kid.lym.inflt./Lg.MNC|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1372|34|266|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1373|34|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma ?\Liv.MNC agg./Kid.int.cell inflt./Lg.alv.eos.sub.,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1374|34|568|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.granuloma/Kid.glom.hyal.&mesang.sclerosis|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1375|34|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LBL),MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1376|34|672|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1377|34|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LCL),MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1378|34|679|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1379|34|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1380|34|728|Neoplasia malignant|Bloodvessels among cardiovascular system|systemic Hemangiosarcoma\Kid.inter.nephritis/Lg.perivasc.inflt.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1381|34|738|Other deterministic changes|Bone among musculo-skeletal system diseases|Perivascul.lym.inflt/Lg.eosin.sub. dep.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1382|34|742|Other deterministic changes|Bone among musculo-skeletal system diseases|autolysis|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1383|34|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\autolysis,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1384|34|763|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Lung alveolar eosinophilic substances deposition|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1385|34|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1386|34|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LBL),MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1387|34|793|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Mandibular carcinoma\Liv.lym.& PC inflt./Pan.interst.lym.inflt.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1388|34|799|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|meta.Kidney carcinoma\Lung alveolar eosinophilic substances deposition,MPATH: 549 - carcinoma|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1389|34|819|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1390|34|840|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1391|34|842|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1392|34|847|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1393|34|858|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hep.hypertrophy/Kid.glom.hyal./Lg.alv.eos.cry.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1394|34|868|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Kid.glomerular hyalinization|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1395|34|885|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1396|34|931|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1397|34|931|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glom.hyalin./Myocard.edema/Alveol.eos.cryst.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1398|34|959|n/a|n/a|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1399|34|973|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1400|34|991|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy, lym./Pan.MNC/Lg.eos.sub.dep.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1640|34|575|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma\Kid.glom.swell.mes.vacuolar deg. & increase|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1641|34|588|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LCL)\Kid.glom.hyal.mes.swell.,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1642|34|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic Lymphoma(B-SLL)\Liv.fatty deg.,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1643|34|658|Neoplasia systemic|Haematolymphatic system|Myeloid(Gr.) leukemia|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1644|34|665|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1645|34|667|Neoplasia malignant|Bloodvessels among cardiovascular system|Hemangiosarcoma\Pan lym.inflt & islet decrease/Kid lym.inflt|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1646|34|693|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1647|34|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Lung alveolar eosinophilic substance deposition,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1648|34|711|Neoplasia malignant|Bloodvessels among cardiovascular system|SC hemangiosarcoma|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1649|34|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1650|34|728|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic crystalline|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1651|34|728|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1652|34|746|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Kid.glomer.hyalinization & mesang.increase|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1653|34|772|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.end.gr., fibrosis & hyalin./Kid.gl.hyal.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1654|34|792|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.eosinophilic crystalline & phagocytosis|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1655|34|805|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|PAC\Kid.glomer.hyalin./Lg.alv.eos.deposits. & crystall,MPATH: 268 - adenocarcinoma|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1656|34|812|Neoplasia malignant|Bloodvessels among cardiovascular system|meta.Hemangiosarcoma|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1657|34|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?\Lg.alveolar eosinophilic crystalline,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1658|34|829|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alveolar eosinophilic deposits|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1659|34|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1660|34|868|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic deposits|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1661|34|882|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy, hyperplasia, fibrosis, PMN|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1662|34|882|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Pan.islet hypertrophy/Lg.bronch.PMN, lym.,MPATH: 218 - neoplasm|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1663|34|913|Other deterministic changes|Bone among musculo-skeletal system diseases|Lg.alv.eos.crystalline/Myocardial granulocytic inf|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1664|34|927|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.PMN,lym.,plasma/Pan.MNC/Lg.eos.sub.&lym.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1665|34|931|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov. Adenocarcinoma\Lg.perivascular plasma cell inflt.,MPATH: 549 - carcinoma|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1666|34|980|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fibrosis/Kid.int.lym.inflt.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1667|34|990|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy/Kid.lym.inflt./Lg.eos.sub. & lym.|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1668|34|996|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.lym.PMN/Kid.lym./Myocard.endothel.fibrosis|
2001-8-34|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-34-1669|34|1015|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.nodular hyperplasia/Lg.alv.eos.crystalline|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1401|35|344|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1402|35|546|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Kid.glom.hyalinization,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1403|35|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma?,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1404|35|423|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1405|35|599|Neoplasia malignant|Endocrine system|Harderian gl. Carcinoma\Coronary arterial medial thickeness|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1406|35|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1407|35|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1408|35|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma(T-LCL),MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1409|35|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1410|35|693|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glom.swell. & mes.increase/Myocarditis|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1411|35|701|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Liv.fatty deg./Sp.G-G body/Glom.hyal.mes.depos.|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1412|35|717|Other deterministic changes|Bone among musculo-skeletal system diseases|CT inflamm./Sp. G-G body/Kid. glomer.scler.|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1413|35|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(T-LBL),MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1414|35|773|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glomer.hyaliniz./Connective tissue growth|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1415|35|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Lg.alveolar eosinophilic crystalline,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1416|35|913|Other deterministic changes|Bone among musculo-skeletal system diseases|Lung alveolar eosinophilic deposit.|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1417|35|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Liv.endothel., Kupffer increase, hypertrophy,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1418|35|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Lg.alveolar eosinophilic crystalline,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1419|35|1036|Other deterministic changes|Bone among musculo-skeletal system diseases|Bl.vessel wall hyalin./Kid.glom.scleros./Lg.eos.cr|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1420|35|491|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1421|35|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1422|35|406|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1423|35|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1424|35|680|Neoplasia malignant|Bone among musculo-skeletal system diseases|meta.Osteosarcoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1425|35|730|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Histiocytic sarcoma(leukemic),MPATH: 409 - fibrous histiocytoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1426|35|736|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1427|35|808|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1428|35|821|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1429|35|870|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1670|35|472|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia ?|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1671|35|434|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1672|35|408|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1673|35|540|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1674|35|546|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1675|35|569|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lynmphoma(Pre-B),MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1676|35|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1677|35|746|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1678|35|763|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1679|35|784|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1680|35|809|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|PAC,MPATH: 268 - adenocarcinoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1681|35|814|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1682|35|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Localized lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1683|35|857|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1684|35|872|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1685|35|876|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1686|35|900|Neoplasia malignant|Other local manifestations and miscellaneus|meta.Carcinoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1687|35|442|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1688|35|238|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1689|35|578|Neoplasia systemic|Haematolymphatic system|Myeloid Neoplasm|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1690|35|588|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov.adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1691|35|665|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|Liver histiocytic sarcoma,MPATH: 551 - sarcoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1692|35|683|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1693|35|742|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1695|35|770|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1696|35|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1697|35|808|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|PAC,MPATH: 268 - adenocarcinoma|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1698|35|858|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1699|35|882|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-35|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-35-1700|35|886|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1228|36|745|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\Pan.mononuclear cell inflt./Adipose lym.inflt.,MPATH: 268 - adenocarcinoma|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1229|36|756|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1230|36|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1231|36|800|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1232|36|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1233|36|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1234|36|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\BM trabecular bone hyperplasia,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1235|36|1072|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertr. & nod.hyperpl.fatty deg./Kid.glom.hya|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1236|36|1093|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.swelling & fatty deg./Cardiac fibrosis|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1237|36|1134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?\Lg.PAM & balloon cells,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1238|36|1138|Neoplasia malignant|Bloodvessels among cardiovascular system|SC Hemangiosarcoma\Liv.hypertrophy & fatty deg.|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1239|36|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?\Myocardial PMN inflt.,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1240|36|685|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1241|36|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Myocardial edema,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1242|36|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty degeneration,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1243|36|856|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mam.squamous cell Ca\Liv.fatty deg./Fatty necrosis,MPATH: 268 - adenocarcinoma|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1244|36|860|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1245|36|875|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg./Kid.lym.inflt./Lg.lym.inflt.|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1246|36|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.nod.hyperplasia, hypertrophy/Pan.islet hyperpl,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1247|36|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1248|36|1028|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1249|36|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1250|36|1077|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-36|n/a,n/a|1|88|shamexposed|0|grays|External exposure|n/a|24 (24 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-36-1251|36|1210|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Kid.glom.hyal.& Ca/Myocard.fat/Lg.hem.& eos.crst.,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1430|37|388|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty&vacuol.deg./Kid.glom.hyal.&scleros.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1431|37|428|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty deg. & necrosis,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1432|37|592|Neoplasia malignant|Bloodvessels among cardiovascular system|Systemic Hemangiosarcoma\Liv.fatty deg.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1433|37|623|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1434|37|644|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1435|37|659|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrosarcoma\Liv.fatty deg./Kid.glom.swell.mes.incr.lym.inflt.,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1436|37|660|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary dysgerminoma\Liv.fatty deg./Kid.glom.hyal.mes.dep.scler./vascul,MPATH: 316 - mixed germ cell tumor|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1437|37|668|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Kid.glom.swell.cap.deposit./Lg.cap.eosin.deposit.,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1438|37|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(B-SLL)\,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1439|37|695|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma\Pan lym.inflt/Myocard.hemorrhage,MPATH: 268 - adenocarcinoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1440|37|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1441|37|714|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Kid.mesangium swelling/Alv.hemosiderin-laden Mf|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1442|37|770|Neoplasia malignant|Bloodvessels among cardiovascular system|Hemangiosarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1443|37|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty deg. & necrosis,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1444|37|819|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1445|37|836|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1446|37|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1447|37|863|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|meta.Abd.fibrosarcoma\Liv.fatty degeneration,MPATH: 408 - soft tissue fibrosarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1448|37|869|Neoplasia systemic|Haematolymphatic system|Myeloid leukemia\Liv/fatty degeneration|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1449|37|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1450|37|917|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1451|37|934|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SC tumor,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1452|37|938|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv.fatty & vacuolar degeneration,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1453|37|953|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1454|37|959|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC\Pan.plasma cell inflt.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1455|37|973|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ov. Tumor,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1456|37|980|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary adenocarcinoma,MPATH: 549 - carcinoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1457|37|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\BM fibrosis & trabecular bone hyperplasia,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1458|37|984|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\Liv.nod.hyperplasia & fatty droplets,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1459|37|996|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma\Pan.int.MNC inflt./Kid.MNC inflt.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1701|37|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1702|37|581|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|S.lymphocytic leukemia\Liv.fatty deg.,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1703|37|671|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1704|37|684|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1705|37|713|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1706|37|715|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty liver/Pan.interstit.lym.inflt.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1707|37|741|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1708|37|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma?,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1709|37|741|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC sarcoma\Liv.fatty deg. & necrosis/Myocardial calcification,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1710|37|759|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv.hypertrophy,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1711|37|762|Neoplasia benign|Lower respiratory system|Pulmonary adenoma\Liv.fatty degeneration|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1712|37|770|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\Liv.necros.fat.deg./Kid,infarct/Pancreatitis/Myoca,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1713|37|771|Other deterministic changes|Bone among musculo-skeletal system diseases|Pan.int.lym.inflt. & islet hypertrophy/Kid.scar|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1714|37|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma?,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1715|37|783|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty degeneration|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1716|37|808|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1717|37|820|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrosarcoma\Kid.pelvis int.lym.inflt.,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1718|37|886|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.glom.hyal., Bowman's fibr.thicken., lym.inflt.|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1719|37|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Kid.Ca deposition,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1720|37|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1721|37|902|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Pan.islet & int.lym.inflt.,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1722|37|909|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1723|37|925|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrosarcoma\Liv.nod.hyperplasia/Sp.hemat./Pan.islet hypertroph,MPATH: 551 - sarcoma|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1724|37|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1725|37|931|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Liv.nod.hyperplasia & hypertrophy/Sp. foll.SSE,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1726|37|938|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg.& MNC & nod.hyperplasia|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1727|37|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.necrosis & hemorrhage,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1728|37|965|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1729|37|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-37|n/a,n/a|1|88|gamma-rays whole body|1|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-37-1730|37|1086|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Liv.hypertrop./Pan.islet hyp.MNC/Kid.glom.hyal.,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1460|38|357|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1461|38|539|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemia,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1462|38|462|Neoplasia malignant|Integumentary system|Basal cell Ca\Liv.fatty droplet|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1463|38|518|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1464|38|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma(Pre-B)\Myocard.calcification,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1465|38|624|Neoplasia systemic|Haematolymphatic system|Myeloid(granuocytic) leukemia|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1466|38|652|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|meta.SC liposarcoma\Kid.int.lym.&plasma cell inflt.,MPATH: 549 - carcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1467|38|665|Neoplasia benign|Lower respiratory system|Pulmonary adenoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1468|38|723|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\Fatty liver/Lung alveolar eosinophilic crystalline,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1469|38|735|Neoplasia unclassified|Central nervous system among nervous system|Brain tumor\Liv.hepat. hypertrophy/Kid.Bowman's deposits|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1470|38|742|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1471|38|742|Neoplasia unclassified|Ovary among reproductive system diseases|Ovary granulosa cell tumor\Kid.mes.hypertrophy & increase/BM trabecular gr.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1472|38|749|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.Glisson's PMN & lym.inflt.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1473|38|756|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary adenocarcinoma\Liv.HC hypertrophy & fatty deg./Kid.mesang.swell.,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1474|38|770|Neoplasia malignant|Liver among hepato-pancreatic system diseases|meta.Hepatocellular carcinoma\Kid.glomerular hyalinization|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1475|38|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Lg.alveolar Mf phagocytosis of eosinophilic sub.,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1476|38|784|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|OvT,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1477|38|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1478|38|805|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|SCT,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1479|38|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1480|38|833|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary adenocarcinoma\Liv.fatty deg./Kid.mes.swell./Int.myocarditis,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1481|38|834|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg./BM fatty dep.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1482|38|843|Neoplasia malignant|Bloodvessels among cardiovascular system|Abd.hemangiosarcoma\Liv.vasc.hyalin./Pan.int.lym.inflt.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1483|38|854|Neoplasia malignant|Other local manifestations and miscellaneus|meta.Liposarcoma\Kid.int.lym.inflt.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1484|38|875|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1485|38|875|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertrophy|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1486|38|877|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\Bone trabecular thicken.,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1487|38|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1488|38|948|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC\Liv.necrosis/Myocardial PMN & lym.inflt.|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1489|38|966|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1731|38|321|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1732|38|281|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1733|38|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Thymic lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1734|38|686|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1735|38|694|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1736|38|702|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|Pancreatic carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1737|38|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1738|38|728|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|meta.SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1739|38|734|Neoplasia unclassified|Endocrine system,MA: 0001247 - harderian gland|meta.Harderian gl.tumor,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1740|38|734|Neoplasia malignant|Liver among hepato-pancreatic system diseases|Hepatocellular carcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1741|38|741|Neoplasia malignant|Endocrine system|Harderian gl.carcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1742|38|748|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1743|38|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1744|38|755|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|meta.Mammary carcinoma,MPATH: 268 - adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1745|38|776|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1746|38|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1747|38|797|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|OvT,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1748|38|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma?,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1749|38|835|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|Thyroid carcinoma,MPATH: 278 - follicular adenocarcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1750|38|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1751|38|840|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1752|38|842|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|meta.Uterus tumor,MPATH: 218 - neoplasm|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1753|38|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1754|38|877|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC carcinoma,MPATH: 446 - squamous cell carcinoma|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1755|38|881|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1756|38|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|localized Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1757|38|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma ?,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1758|38|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-38|n/a,n/a|1|88|gamma-rays whole body|2|grays|External exposure|n/a|59 (59 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-38-1759|38|1014|Neoplasia malignant|Liver among hepato-pancreatic system diseases|meta.Hepatocellular Ca|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1490|39|469|Other deterministic changes|Bone among musculo-skeletal system diseases|Kid.basophilic glom.& plasma cell inflt.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1491|39|434|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty liver,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1492|39|548|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Leukemic lymphoma\Fatty liv. & necr./Pancreatitis/Kid.int.cell inflt,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1493|39|581|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty droplet/Pancreas islet hypertrophy|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1494|39|585|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mam.adenocarcinoma\Fatty liv./Myocard.calcification & necrosis,MPATH: 268 - adenocarcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1495|39|609|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty liv./Myocard.fibrosis/Lg.atelectasis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1496|39|616|Neoplasia systemic|Haematolymphatic system|Myeloid Leukemia|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1497|39|665|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1498|39|666|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|Thyroid carcinoma,MPATH: 278 - follicular adenocarcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1499|39|668|Neoplasia malignant|Endocrine system|meta.Harderian gl.adenocarcinoma\Liv.ct.hyal./Sp.vasc.hyal./Pan.ct.hyal./Kid.glom.h|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1500|39|699|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1501|39|730|Neoplasia malignant|Other local manifestations and miscellaneus|meta.Carcinoma\Kid.mesangial increase/Pan.islet hypertrophy|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1502|39|739|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\Kid.glom.capillary dilatation & mesangial increase,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1503|39|739|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma,MPATH: 551 - sarcoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1504|39|742|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.glysson's amyloidosis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1505|39|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1506|39|749|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1507|39|777|Neoplasia malignant|Endocrine system|meta.Harderian carcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1508|39|784|Other deterministic changes|Bone among musculo-skeletal system diseases|Heart myocardial fibrosis & lym.inflt.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1509|39|795|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.necrosis & fatty deg./Sp.G-G body/Kid.gl.hyal.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1510|39|818|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor\Liv.hypertrophy,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1511|39|818|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty liver|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1512|39|861|Neoplasia malignant|Bloodvessels among cardiovascular system|SC hemangiosarcoma\Liv.hypertrophy/Sp.necrosis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1513|39|868|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|Ovary tumor ?\Liv.fatty degeneration,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1514|39|885|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty degeneration & necrosis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1515|39|921|Neoplasia unclassified|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|Adrenal tumor\Liv.hypertrophy, reg., hyperplasia/Kid. Ca deposit,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1516|39|946|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Liv.necr.fatty droplets/Lg.hemosiderin-laden MF,MPATH: 551 - sarcoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1517|39|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Histiocytic sarcoma\Liv.necrosis & fatty degeneration,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1518|39|973|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|Abdominal tumor,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1519|39|987|Neoplasia malignant|Other local manifestations and miscellaneus|meta.Ovary carcinoma\Liv.nod.hyperplasia & fatty droplets|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1760|39|301|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1761|39|398|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.fatty deg.,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1762|39|325|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1763|39|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1764|39|489|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1765|39|524|Other deterministic changes|Bone among musculo-skeletal system diseases|Fatty liver/Inflammation of fat tissues|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1766|39|561|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty droplet/Pancreas fat replace.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1767|39|563|Neoplasia malignant|Bone among musculo-skeletal system diseases|Osteosarcoma\Liv.focal necrosis/Lg.atelectasis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1768|39|574|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic Osteosarcoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1769|39|608|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty deg.&necrosis/Kid.glom.swell.lym.inflt.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1770|39|629|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1771|39|660|Other deterministic changes|Bone among musculo-skeletal system diseases|BM fibrosis & trabecular proliferation|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1772|39|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1773|39|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1774|39|665|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|SC fibrosarcoma\Pan.int.lym.inflt.,MPATH: 551 - sarcoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1775|39|668|Neoplasia malignant|Other local manifestations and miscellaneus|Liposarcoma\|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1776|39|671|Other deterministic changes|Bone among musculo-skeletal system diseases|n/a|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1777|39|673|Neoplasia malignant|Endocrine system|meta.Harderian adenocarcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1778|39|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1779|39|720|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.fatty degeneration|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1780|39|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1781|39|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|Pulmonary adenocarcinoma\Liv.fatty deg./Sp.vasculariz./Pan.lym.inflt.,MPATH: 268 - adenocarcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1782|39|755|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|meta.Ovary tumor\BM.trabecular bone growth,MPATH: 218 - neoplasm|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1783|39|762|Other deterministic changes|Bone among musculo-skeletal system diseases|Liv.hypertropgy & hyperplasia/BM fibrosis|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1784|39|765|Neoplasia malignant|Endocrine system|meta.Harderian carcinoma|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1785|39|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma\Liv.necrosi&fatty deg./Kid.glom.hyal./Heart edema,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1786|39|793|Neoplasia malignant|Endocrine system|meta.HCC\Pan.islet hypertrophy|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1787|39|828|Neoplasia malignant|Liver among hepato-pancreatic system diseases|HCC\Pan.islet hypertrophy/Kid.cast & Bowmans thick.|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1788|39|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Lymphoma,MPATH: 513 - Lymphoid neoplasms|
2001-8-39|n/a,n/a|1|88|gamma-rays whole body|3|grays|External exposure|n/a|60 (60 in ERA)|Mouse|Mouse, BC3F1 (C57Bl/CnexC3H/Cne)F|Female|Young Adult|lifespan study|2001-8-39-1789|39|959|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|Mammary adenocarcinoma\Liv.nod.hyp.MNC/Kid.lym./Myocard.necr.lym.,MPATH: 268 - adenocarcinoma|
